Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 401–500 of 4,628
Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis
Jones, M. G., Fabre, A., Schneider, P., Cinetto, F., Sgalla, G., Mavrogordato, M., Jogai, S., Alzetani, A., Marshall, B. G., O’Reilly, K. M. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86375 · Cited by 95
Self-citationGuzy, R. D., Stoilov, I., Elton, T. J., Mecham, R. P., & Ornitz, D. M. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0184oc · Cited by 95
Raghu, G., Richeldi, L., Jagerschmidt, A., Martin, V., Subramaniam, A., Ozoux, M.-L., Esperet, C. A., & Soubrane, C. (2018) · Chest · doi:10.1016/j.chest.2018.08.1083 · Cited by 95
Self-citationRicheldi, L., Varone, F., Bergna, M., de Andrade, J., Falk, J., Hallowell, R., Jouneau, S., Kondoh, Y., Morrow, L., Randerath, W., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0074-2018 · Cited by 95
Self-citationBing, P., Zhou, W., & Tan, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.865065 · Cited by 106
Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF
Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V., Marlow, M. M., Kotak, P., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01863-0 · Cited by 94
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review
Iqbal, K., & Kelly, C. A. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15612250 · Cited by 107
Reddy, M., Fonseca, L., Gowda, S., Chougule, B., Hari, A., & Totey, S. (2016) · International Journal of Stem Cells · doi:10.15283/ijsc16041 · Cited by 93
Fibulin-1c regulates transforming growth factor–β activation in pulmonary tissue fibrosis
Liu, G., Cooley, M. A., Jarnicki, A., Borghuis, T., Nair, P. M., Tjin, G., Hsu, A., Haw, T. J., Fricker, M., Harrison, C. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124529 · Cited by 110
“Both drugs delay the impairment of lung function and improve the survival rate of patients with IPF (6, 15).”
BackgroundVascular permeability in the fibrotic lung
Probst, C. K., Montesi, S. B., Medoff, B. D., Shea, B. S., & Knipe, R. S. (2020) · European Respiratory Journal · doi:10.1183/13993003.00100-2019 · Cited by 94
mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis
Gui, Y.-S., Wang, L., Tian, X., Li, X., Ma, A., Zhou, W., Zeng, N., Zhang, J., Cai, B., Zhang, H., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138625 · Cited by 94
Evaluating disease severity in idiopathic pulmonary fibrosis
Robbie, H., Daccord, C., Chua, F., & Devaraj, A. (2017) · European Respiratory Review · doi:10.1183/16000617.0051-2017 · Cited by 93
Idiopathic pulmonary fibrosis and cancer: do they really look similar?
Vancheri, C. (2015) · BMC Medicine · doi:10.1186/s12916-015-0478-1 · Cited by 94
Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy
Distler, O., & Cozzio, A. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0551-z · Cited by 104
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
Johannson, K. A., Strambu, I. R., Ravaglia, C., Grutters, J. C., Valenzuela, C., Moğulkoç, N., Luppi, F., Richeldi, L., Wells, A. U., Vancheri, C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30219-9 · Cited by 101
Self-citationMarshall, D. C., Salciccioli, J. D., Shea, B. S., & Akuthota, P. (2018) · European Respiratory Journal · doi:10.1183/13993003.01603-2017 · Cited by 100
LOX/LOXL in pulmonary fibrosis: potential therapeutic targets
Chen, L., Li, S., & Li, W. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1550649 · Cited by 96
on behalf of the IPF-PRO Registry investigators, Todd, J. L., Neely, M. L., Overton, R., Durham, K., Gulati, M., Huang, H., Roman, J., Newby, L. K., Flaherty, K. R., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1190-z · Cited by 93
Self-citationMonocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis
Perrot, C. Y., Karampitsakos, Τ., & Herazo‐Maya, J. D. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00302.2023 · Cited by 104
Moeini, A., Torrecilla, S., Tovar, V., Montironi, C., Andreu-Oller, C., Peix, J., Higuera, M., Pfister, D., Ramadori, P., Pinyol, R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.028 · Cited by 92
Gordon, J. K., Martyanov, V., Magro, C., Wildman, H. F., Wood, T. A., Huang, W.-T., Crow, M. K., Whitfield, M. L., & Spiera, R. F. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0721-3 · Cited by 92
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease
Caron, M., Hoa, S. A.-T., Hudson, M., Schwartzman, K., & Steele, R. J. (2018) · European Respiratory Review · doi:10.1183/16000617.0102-2017 · Cited by 96
Tzilas, V., Bouros, E., Barbayianni, I., Karampitsakos, T., Kourtidou, S., Ntassiou, M., Ninou, I., Aidinis, V., Bouros, D. E., & Τzouvelekis, Α. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.01.003 · Cited by 102
Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.
Juarez, M. M., Chan, A. L., Norris, A., Morrissey, B. M., & Albertson, T. E. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.01.17 · Cited by 114
Raghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. K., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2213so · Cited by 92
Self-citationCurrent approaches to the management of idiopathic pulmonary fibrosis
Raghu, G., & Richeldi, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.05.017 · Cited by 90
Self-citationThe Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Saito, A., Horie, M., Micke, P., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113611 · Cited by 90
“These agents slow disease progression [98,99], and recent meta-analyses have demonstrated that these agents have a beneficial impact on survival [100,101].”
BackgroundInterstitial Lung Diseases in Developing Countries
Rivera‐Ortega, P., & Molina‐Molina, M. (2019) · Annals of Global Health · doi:10.5334/aogh.2414 · Cited by 104
Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes
Wakwaya, Y. T., & Brown, K. M. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.013 · Cited by 97
Self-citationLung transplantation for interstitial lung disease
Kapnadak, S. G., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0017-2021 · Cited by 91
Self-citationHanda, T., Tanizawa, K., Oguma, T., Uozumi, R., Watanabe, K., Tanabe, N., Niwamoto, T., Shima, H., Mori, R., Nobashi, T. W., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202101-044oc · Cited by 103
The St. George’s Respiratory Questionnaire as a prognostic factor in IPF
Furukawa, T., Taniguchi, H., Ando, M., Kondoh, Y., Kataoka, K., Nishiyama, O., Johkoh, T., Fukuoka, J., Sakamoto, K., & Hasegawa, Y. (2017) · Respiratory Research · doi:10.1186/s12931-017-0503-3 · Cited by 99
Self-citationLung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Jafarinezhad, A., & YektaKooshali, M. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202360 · Cited by 98
Cameli, P., Refini, R. M., Bergantini, L., d’Alessandro, M., Alonzi, V., Magnoni, C., Rottoli, P., Sestini, P., & Bargagli, E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.581828 · Cited by 89
Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis
Kropski, J. A., Young, L. R., Cogan, J. D., Mitchell, D. B., LANCASTER, L. H., Worrell, J. A., Markin, C. R., Liu, N., Mason, W. R., Fingerlin, T. E., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1820pp · Cited by 104
Nintedanib for the treatment of idiopathic pulmonary fibrosis
Varone, F., Sgalla, G., Iovene, B., Bruni, T., & Richeldi, L. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1425681 · Cited by 98
Self-citationKreuter, M., Bonella, F., Wijsenbeek, M., Maher, T. M., & Spagnolo, P. (2015) · BioMed Research International · doi:10.1155/2015/329481 · Cited by 87
“Until this diagnostic approach is validated prospectively, we recommend patients with possible or probable IPF be referred to expert centers for further management.”
MethodO'Dwyer, D. N., Ashley, S. L., & Moore, B. B. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00221.2016 · Cited by 88
Çınar, R., Gochuico, B. R., Iyer, M. R., Jourdan, T., Yokoyama, T., Park, J. K., Coffey, N. J., Pri‐Chen, H., Szanda, G., Liu, Z., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92281 · Cited by 97
Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor
Maillet, T., Goletto, T., Beltramo, G., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102338 · Cited by 89
Self-citationMoor, C. C., Oppenheimer, J. C., Nakshbandi, G., Aerts, J. G. J. V., Brinkman, P., der Zee, A. H. M., & Wijsenbeek, M. S. (2020) · European Respiratory Journal · doi:10.1183/13993003.02042-2020 · Cited by 93
Peritubular Capillary Rarefaction: An Underappreciated Regulator of CKD Progression
Kida, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218255 · Cited by 105
“Although the most frequent adverse effect of nintedanib was diarrhea, more than 95% of patients tolerated the drug intake during the study period [167].”
BackgroundInfluentialMarchioni, A., Tonelli, R., Ball, L., Fantini, R., Castaniere, I., Cerri, S., Luppi, F., Malerba, M., Pelosi, P. P., & Clini, E. M. (2018) · Critical Care · doi:10.1186/s13054-018-2002-4 · Cited by 95
Doubková, M., Švancara, J., Svoboda, M., Šterclová, M., Bartoš, V., Plačková, M., Lacina, L., Žurková, M., Binková, I., Bittenglová, R., et al. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12700 · Cited by 87
Recent advances in understanding idiopathic pulmonary fibrosis
Daccord, C., & Maher, T. M. (2016) · F1000Research · doi:10.12688/f1000research.8209.1 · Cited by 87
Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
Oldham, J. M., & Collard, H. R. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00123 · Cited by 98
Self-citationDhooria, S., Agarwal, R., Sehgal, I. S., Prasad, K. T., Garg, M. K., Bal, A., Aggarwal, A. N., & Behera, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191938 · Cited by 95
Pirfenidone improves survival in IPF: results from a real-life study
Margaritopoulos, G. A., Trachalaki, A., Wells, A. U., Vasarmidi, E., Bibaki, E., Papastratigakis, G., Detorakis, S., Tzanakis, N., & Antoniou, K. M. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0736-z · Cited by 87
Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis
Bellan, M., Cittone, M. G., Tonello, S., Rigamonti, C., Castello, L. M., Gavelli, F., Pirisi, M., & Sainaghi, P. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205070 · Cited by 85
Hyldgaard, C., Ellingsen, T., Hilberg, O., & Bendstrup, E. M. (2019) · Respiration · doi:10.1159/000502551 · Cited by 98
Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection
Mylvaganam, R. J., Bailey, J. I., Sznajder, J. I., & Sala, M. A. (2021) · European Respiratory Review · doi:10.1183/16000617.0194-2021 · Cited by 105
Dong, S.-H., Liu, Y., Wei, F., Tan, H., & Han, Z.-D. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.005 · Cited by 89
Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis
Johannson, K. A., Vittinghoff, E., Morisset, J., Lee, J. S., Balmes, J. R., & Collard, H. R. (2017) · European Respiratory Journal · doi:10.1183/13993003.02406-2016 · Cited by 101
Self-citationPirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial
Sakamoto, S., Kataoka, K., Kondoh, Y., Kato, M., Okamoto, M., Mukae, H., Bando, M., Suda, T., Yatera, K., Tanino, Y., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00348-2020 · Cited by 67
Caveolin-1–derived peptide limits development of pulmonary fibrosis
Marudamuthu, A. S., Bhandary, Y. P., Fan, L., Radhakrishnan, V., MacKenzie, B., Maier, E., Shetty, S. K., Nagaraja, M. R., Gopu, V., Tiwari, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat2848 · Cited by 86
“Nintedanib, a broad-spectrum tyrosine kinase inhibitor, also slowed the progression of disease in patients with IPF (5).”
BackgroundTian, S., Yang, Y., Liu, X., & Xu, Q. (2018) · Medical Science Monitor · doi:10.12659/msm.905496 · Cited by 86
Redente, E. F., Aguilar, M., Black, B. P., Edelman, B., Bahadur, A. N., Humphries, S. M., Lynch, D. A., Wollin, L., & Riches, D. W. H. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00304.2017 · Cited by 96
Umemura, Y., Mitsuyama, Y., Minami, K., Nishida, T., Watanabe, A., Okada, N., Yamakawa, K., Nochioka, K., & Fujimi, S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.055 · Cited by 103
Durheim, M. T., Collard, H. R., Roberts, R. S., Brown, K. K., Flaherty, K. R., King, T. E., Palmer, S. M., Raghu, G., Snyder, L. D., Anstrom, K. J., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00093-4 · Cited by 87
Self-citationGilhodes, J.-C., Julé, Y., Kreuz, S., Stierstorfer, B., Stiller, D., & Wollin, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170561 · Cited by 98
Rivera‐Ortega, P., Hayton, C., Blaikley, J., Leonard, C. T., & Chaudhuri, N. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618800618 · Cited by 90
Lung complications of Sjogren syndrome
Luppi, F., Sebastiani, M., Sverzellati, N., Cavazza, A., Salvarani, C., & Manfredi, A. (2020) · European Respiratory Review · doi:10.1183/16000617.0021-2020 · Cited by 97
Otsubo, K., Kishimoto, J., Ando, M., Kenmotsu, H., Minegishi, Y., Horinouchi, H., Kato, T., Ichihara, E., Kondo, M., Atagi, S., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00380-2022 · Cited by 98
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
Kreuter, M., Bonella, F., Maher, T. M., Costabel, U., Spagnolo, P., Weycker, D., Kirchgaessler, K.-U., & Kolb, M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208819 · Cited by 85
Self-citationUncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis
Shea, B. S., Probst, C. K., Brazee, P. L., Rotile, N. J., Blasi, F., Weinreb, P. H., Black, K. E., Sosnovik, D. E., Cott, E. M. V., Violette, S. M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.86608 · Cited by 88
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
Spagnolo, P., Maher, T. M., & Richeldi, L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.005 · Cited by 94
Self-citationSohal, S. S., Mahmood, M. Q., & Walters, E. H. (2014) · Clinical and Translational Medicine · doi:10.1186/s40169-014-0033-2 · Cited by 86
Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis
Bahmer, T., Kirsten, A.-M., Waschki, B., Rabe, K. F., Magnussen, H., Kirsten, D., Gramm, M., Hummler, S., Brunnemer, E., Kreuter, M., et al. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0444-0 · Cited by 84
Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis
Murray, L. A., Habiel, D. M., Hohmann, M., Camelo, A., Shang, H., Zhou, Y., Coelho, A. L., Peng, X., Gulati, M., Crestani, B., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92192 · Cited by 85
Jin, Y. H., Xu, Z., Yan, H., He, Q., Yang, X., & Luo, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00891 · Cited by 91
Lang, N. J., Gote-Schniering, J., Porras-Gonzalez, D., Yang, L., Sadeleer, L. D., Jentzsch, R. C., Shitov, V. A., Zhou, S., Ansari, M., Agami, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh0908 · Cited by 104
Pharmacologic inhibition of lactate production prevents myofibroblast differentiation
Kottmann, R. M., Trawick, E. C., Judge, J., Wahl, L. A., Epa, A. P., Owens, K. M., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00058.2015 · Cited by 91
Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a Review
Zaman, T., & Lee, J. S. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0210-7 · Cited by 97
Long‐term outcomes in chronic hypersensitivity pneumonitis
Ojanguren, Í., Morell, F., Ramón, M. A., Villar, A., Mesones, C. E. R., Cruz, M. J., & Muñoz, X. (2019) · Allergy · doi:10.1111/all.13692 · Cited by 91
“Indeed, in similar processes such as IPF or connective tissue disease‐associated ILD, which show a reduction in these parameters as occurs in CHP,(31,32) there is increasing consensus to adding DLCO values not only for the diagnosis and management,(33) but also for evaluating response to new drugs in clinical trials.(…”
BackgroundNintedanib in children and adolescents with fibrosing interstitial lung diseases
Deterding, R. R., Young, L. R., DeBoer, E. M., Warburton, D., Cunningham, S., Schwerk, N., Flaherty, K. R., Brown, K. K., Dumistracel, M., Erhardt, E. M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01512-2022 · Cited by 92
Self-citationImpact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival
Kanaji, N., Tadokoro, A., Kita, N., Murota, M., Ishii, T., Takagi, T., Watanabe, N., Tojo, Y., Harada, S., Hasui, Y., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2199-z · Cited by 84
Margaritopoulos, G., Vasarmidi, E., & Antoniou, K. (2016) · Core Evidence · doi:10.2147/ce.s76549 · Cited by 81
Adegunsoye, A., Alqalyoobi, S., Linderholm, A., Bowman, W. S., Lee, C. T., Pugashetti, J. V., Sarma, N., Ma, S.-F., Haczku, A., Sperling, A., et al. (2020) · Chest · doi:10.1016/j.chest.2020.04.066 · Cited by 82
Seibold, J. R., Maher, T. M., Highland, K. B., Assassi, S., Azuma, A., Hummers, L. K., Costabel, U., von Wangenheim, U., KOHLBRENNER, V. M., Gahlemann, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217331 · Cited by 87
Self-citationLung Fibrosis and Fibrosis in the Lungs: Is It All about Myofibroblasts?
Zapater, E. O., Signes‐Costa, J., Montero, P., & Roger, I. (2022) · Biomedicines · doi:10.3390/biomedicines10061423 · Cited by 94
Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside
Ghonim, M. A., Boyd, D. F., Flerlage, T., & Thomas, P. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170499 · Cited by 95
Soltanmohammadi, F., Gharehbaba, A. M., Zangi, A. R., Adibkia, K., & Javadzadeh, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117248 · Cited by 95
Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis
Barratt, S. L., Blythe, T., Jarrett, C., Ourradi, K., Shelley‐Fraser, G., Day, M. J., Qiu, Y., Harper, S. J., Maher, T. M., Oltean, S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201603-0568oc · Cited by 89
Treatment of Interstitial Lung Disease Associated Cough
Birring, S. S., Kavanagh, J. E., Irwin, R. S., Keogh, K. A., Lim, K. G., Ryu, J. H., Adams, T. M., Altman, K. W., Azoulay, É., Barker, A. F., et al. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.06.038 · Cited by 87
Abramson, M. J., Murambadoro, T., Alif, S. M., Benke, G. P., Dharmage, S. C., Glaspole, I., Hopkins, P., Hoy, R. F., Klebe, S., Moodley, Y., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-214478 · Cited by 80
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods
Wang, B. R., Edwards, R., Freiheit, E., Ma, Y., Burg, C., de Andrade, J. A., LANCASTER, L. H., Lindell, K. O., Nathan, S. D., Raghu, G., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202001-035sd · Cited by 84
Self-citationRegulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 88
Small Airway Reduction and Fibrosis Is an Early Pathologic Feature of Idiopathic Pulmonary Fibrosis
Ikezoe, K., Hackett, T., Peterson, S., Prins, D., Hague, C. J., Murphy, D. T., Ledoux, S., Chu, F. S. F., Xu, F., Cooper, J. D., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202103-0585oc · Cited by 90
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
Zhang, D., Adegunsoye, A., Oldham, J. M., Kozlitina, J., Garcia, N. M., Poonawalla, M., Strykowski, R. K., Linderholm, A., Ley, B., Ma, S., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00441-2023 · Cited by 95
Advances in Understanding of the Pathogenesis of Acute Respiratory Distress Syndrome
Sharp, C., Millar, A., & Medford, A. R. L. (2015) · Respiration · doi:10.1159/000381102 · Cited by 82
Park, H. J., Lee, S. M., Song, J. W., Lee, S. M., Oh, S. Y., Kim, N., & Seo, J. B. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.16.16054 · Cited by 88
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0636oc · Cited by 80
Self-citationReal-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Brunnemer, E., Wälscher, J., Ehlers-Tenenbaum, S., Hausmanns, J., Schulze, K., Seiter, M., Heußel, C. P., Warth, A., Herth, F. J. F., & Kreuter, M. (2018) · Respiration · doi:10.1159/000485933 · Cited by 83
Wong, A. W., Fidler, L. M., Marcoux, V. S., Johannson, K. A., Assayag, D., Fisher, J. H., Hambly, N., Kolb, M. R. J., Morisset, J., Shapera, S., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.019 · Cited by 94
“[24] [25] [26] The current difficulty in obtaining PFTs and conducting MDDs in places with a high burden of COVID-19 will limit fulfillment of these criteria.”
Self-citationPhase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
Maher, T. M., Costabel, U., Glassberg, M. K., Kondoh, Y., Ogura, T., Scholand, M. B., Kardatzke, D., Howard, M., Olsson, J., Neighbors, M., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02442-2019 · Cited by 79
Self-citationLin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 91
Matteson, E. L., Aringer, M., Burmester, G. R., Mueller, H., Moros, L., & Kolb, M. R. J. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06623-7 · Cited by 96
Self-citationPamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
Raghu, G., Richeldi, L., Pérez, E. R. F., Salvo, M. C. D., Silva, R. S., Song, J. W., Ogura, T., Xu, Z., Belloli, E. A., Zhang, X., et al. (2024) · JAMA · doi:10.1001/jama.2024.8693 · Cited by 104
Self-citationUnclassifiable interstitial lung disease: A review
Skolnik, K., & Ryerson, C. J. (2015) · Respirology · doi:10.1111/resp.12568 · Cited by 89
Miura, Y., Saito, T., Tanaka, T., Takoi, H., Yatagai, Y., Inomata, M., Nei, T., Saito, Y., Gemma, A., & Azuma, A. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.09.007 · Cited by 94
Self-citation
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.